TMAO furtherpromotes atherosclerosis by activating the CD36-dependent MAPK/Janus kinases(JAKs) pathway and triggering the expression of VCAM-1, TNF-α andIL-1β via the NF-κB pathway [125, 126]. The gene discussed is CD36; the disease is atherosclerosis.